These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 21270326)
1. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. Rosencrantz MA; Coffler MS; Haggan A; Duke KB; Donohue MC; Shayya RF; Su HI; Chang RJ J Clin Endocrinol Metab; 2011 Apr; 96(4):1106-13. PubMed ID: 21270326 [TBL] [Abstract][Full Text] [Related]
2. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867 [TBL] [Abstract][Full Text] [Related]
3. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303 [TBL] [Abstract][Full Text] [Related]
4. Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome. Wachs DS; Coffler MS; Malcom PJ; Shimasaki S; Chang RJ J Clin Endocrinol Metab; 2008 May; 93(5):1827-33. PubMed ID: 18285408 [TBL] [Abstract][Full Text] [Related]
5. Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome. Maas KH; Chuan SS; Cook-Andersen H; Su HI; Duleba A; Chang RJ J Clin Endocrinol Metab; 2015 Jan; 100(1):293-300. PubMed ID: 25313914 [TBL] [Abstract][Full Text] [Related]
6. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Koivunen RM; Morin-Papunen LC; Ruokonen A; Tapanainen JS; Martikainen HK Hum Reprod; 2001 Dec; 16(12):2546-51. PubMed ID: 11726572 [TBL] [Abstract][Full Text] [Related]
7. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome. Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681 [TBL] [Abstract][Full Text] [Related]
8. Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome. Cook-Andersen H; Chuan SS; Maas K; Rosencrantz MA; Su HI; Lawson M; Mason HD; Chang RJ J Clin Endocrinol Metab; 2015 Jan; 100(1):251-7. PubMed ID: 25303490 [TBL] [Abstract][Full Text] [Related]
9. 17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome. Hou J; Cook-Andersen H; Su HI; Shayya R; Maas KH; Burt-Solorzano CM; Kumar A; Chang RJ J Pediatr Endocrinol Metab; 2016 Jul; 29(7):835-40. PubMed ID: 27166718 [TBL] [Abstract][Full Text] [Related]
10. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome. Maas KH; Chuan S; Harrison E; Cook-Andersen H; Duleba AJ; Chang RJ Fertil Steril; 2016 Oct; 106(5):1252-1257. PubMed ID: 27473350 [TBL] [Abstract][Full Text] [Related]
11. Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome. Shayya RF; Rosencrantz MA; Chuan SS; Cook-Andersen H; Roudebush WE; Irene Su H; Shimasaki S; Chang RJ Fertil Steril; 2014 Jan; 101(1):275-9. PubMed ID: 24188875 [TBL] [Abstract][Full Text] [Related]
12. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736 [TBL] [Abstract][Full Text] [Related]
13. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795 [TBL] [Abstract][Full Text] [Related]
14. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome. Mehta RV; Malcom PJ; Chang RJ J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036 [TBL] [Abstract][Full Text] [Related]
15. Characterization of functionally typical and atypical types of polycystic ovary syndrome. Hirshfeld-Cytron J; Barnes RB; Ehrmann DA; Caruso A; Mortensen MM; Rosenfield RL J Clin Endocrinol Metab; 2009 May; 94(5):1587-94. PubMed ID: 19240152 [TBL] [Abstract][Full Text] [Related]
16. Comparison of follicle-stimulating-hormone-stimulated dimeric inhibin and estradiol responses as indicators of granulosa cell function in polycystic ovary syndrome and normal women. Wachs DS; Coffler MS; Malcom PJ; Chang RJ J Clin Endocrinol Metab; 2006 Aug; 91(8):2920-5. PubMed ID: 16720653 [TBL] [Abstract][Full Text] [Related]
17. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. McCartney CR; Bellows AB; Gingrich MB; Hu Y; Evans WS; Marshall JC; Veldhuis JD Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E902-8. PubMed ID: 14736706 [TBL] [Abstract][Full Text] [Related]
18. Individual 17-Hydroxyprogesterone Responses to hCG Are Not Correlated With Follicle Size in Polycystic Ovary Syndrome. Homer MV; Toloubeydokhti T; Lawson MA; Garzo G; Duleba AJ; Chang RJ J Endocr Soc; 2019 Apr; 3(4):687-698. PubMed ID: 30918916 [TBL] [Abstract][Full Text] [Related]
19. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. Adams JM; Taylor AE; Crowley WF; Hall JE J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031 [TBL] [Abstract][Full Text] [Related]
20. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Moran C; Reyna R; Boots LS; Azziz R Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]